IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Adnan M, Khan S, Thasleem H, Imran J, et al. J Gastroenterol 2026 Feb 21. doi: 10.1007/s00535-026-02360.

Read + Share

Amedeo Smart

Independent Medical Education

Adnan M, Khan S, Thasleem H, Imran J, et al. IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol 2026 Feb 21. doi: 10.1007/s00535-026-02360.
PMID: 41721870